{
    "nctId": "NCT05491057",
    "briefTitle": "Treatment Patterns of Neratinib in HER2+ EBC in China",
    "officialTitle": "A Multicenter, Open-label, Single-arm, Non-interventional Study to Investigate the Treatment Patterns of Nerlynx\u00ae (Neratinib) in HER2-positive Early-stage Breast Cancer in China",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 500,
    "primaryOutcomeMeasure": "Duration of Treatment",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Signed written informed consent approved by the reviewing Ethics Committee (EC).\n* Adult patients (\u226518 years of age, no upper limit).\n* Eligible to receive neratinib for extended adjuvant treatment as per prescribing information in China, diagnosed with HER2 overexpressing/amplified early-stage breast cancer regardless of hormone receptor (HR) status and clinical/radiological assessed to be negative for recurrences or metastatic disease.\n\nExclusion Criteria:\n\n* Presence of any contraindication with regard to the neratinib treatment.\n* Current or upcoming participation in an interventional clinical trial. (Investigational treatment within four weeks of enrolment).",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}